FBXW7 and colorectal carcinoma: In colorectal cancer (CRC), FBXW7 loss confers resistance to oxaliplatin and cisplatin chemotherapeutic agents, while CRC cell lines harboring FBXW7 mutations or deletions are more sensitive to rapamycin treatment.